Wall Street Zen lowered shares of CAMP4 Therapeutics (NASDAQ:CAMP – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
A number of other research analysts have also recently commented on the company. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Chardan Capital lowered their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.86.
View Our Latest Research Report on CAMP4 Therapeutics
CAMP4 Therapeutics Price Performance
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The company had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Research analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.
Insider Buying and Selling at CAMP4 Therapeutics
In other news, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kelly Gold bought 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. Insiders own 21.69% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAMP. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the second quarter worth $78,000. Trails Edge Capital Partners LP bought a new position in shares of CAMP4 Therapeutics during the second quarter valued at $8,446,935. Jupiter Topco LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth about $27,581,000. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth about $25,647,928. Finally, BlackRock Inc. purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth about $7,185,000.
About CAMP4 Therapeutics
CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.
CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.
Read More
- Five stocks we like better than CAMP4 Therapeutics
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
